Global Study to Assess the Safety and Effectiveness of Edoxaban (DU-176b) vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation

Inclusion Criteria:

- 21 years of age or older; male or female.

- Able to provide written informed consent.

- History of documented AF within the prior 12 months

- A moderate to high risk of stroke, as defined by CHADS2 index score of at least 2

Exclusion Criteria:

- Transient atrial fibrillation secondary to other reversible disorders

- Subjects with moderate or severe mitral stenosis, unresected atrial myxoma, or a
mechanical heart valve

- Subjects with any contraindication for anticoagulant agents;

- Subjects with conditions associated with high risk of bleeding or have known or
suspected hereditary or acquired bleeding disorders

- Females of childbearing potential including the following:

- Females with a history of tubal-ligation

- Females less than 2 years post-menopausal